Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, has extended its series B round by €18m ($22m) thanks to its existing investor base. These shareholders are European Molecular Biology Laboratory’s EMBL Ventures, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical firm Boehringer Ingelheim’s Venture Fund, Gimv Vesalius BioCapital III and BioMedPartners. Topas previously obtained an initial $26m in series B funding in October 2020 co-led by Vesalius BioCaptial III and BioMed Partners, when EMBL Ventures, Epidarex Capital, Evotec, Boehringer Ingelheim’s Venture Fund and Gimv also contributed. Founded in 2003, Topas Therapeutics is working on therapies for autoimmune diseases. Its lead asset, TPM203, is aimed at pemphigus vulgaris – which causes painful blistering. The company also has a proposed treatment for coeliac disease, TPM501, that is expected to enter the clinic by the end of this year. The funding will also allow Topas to advance several preclinical assets, including one for rheumatoid arthritis and one for type 1 diabetes. Topas completed a $20.6m series A round in 2017 backed by Epidarex Capital, EMBL Ventures, Evotec, Boehringer Ingelheim Venture Fund and Gimv.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).